Articles tagged with Amyloids
Researchers propose using blood-brain barrier breakdown as an early warning sign for Alzheimer's disease, which could lead to earlier diagnosis and treatment. Healthy blood vessels are crucial for normal brain functioning, and damage can be detected with imaging tests such as MRI.
Researchers identified SynuClean-D as a potential therapeutic for neurodegeneration, which disrupts amyloid fibrils and inhibits alpha-synuclein aggregation. The compound reversed degeneration of dopaminergic neurons in animal models, offering hope for halting Parkinson's disease-related neurodegeneration.
Researchers have devised a novel strategy to identify people with mild cognitive impairment at risk of developing Alzheimer's disease. The Loewenstein-Acevedo Scales for Semantic Interference and Learning (LASSI-L) tool measures specific memory deficits that align with imaging findings for abnormal brain amyloid accumulation.
Researchers at Washington University in St. Louis create 'blink' method to image amyloids, allowing for non-invasive visualization of these problematic proteins. The technique uses temporary fluorescence, causing amyloids to flash and enabling researchers to better understand their structure and behavior.
A phase three clinical trial has shown that tafamidis can reduce deaths by 30% and cardiovascular-related hospitalizations by 32%. The treatment also slows the decline in quality of life among patients with transthyretin amyloid cardiomyopathy. If approved, it would be the first medical therapy for this life-threatening disease.
Researchers have developed tools to break down pesticides in the environment using catalytic amyloids. The discovery shows that these molecules can facilitate multiple chemical transformations at once, offering a promising approach for OP detoxification. Catalytic amyloids have been shown to hydrolyze paraoxon by several thousand-fold.
Tafamidis improves survival and quality of life, reducing hospitalizations in patients with transthyretin amyloid cardiomyopathy. The therapy delays neurologic progression in a similar condition, and has been approved for this condition in the EU.
Scientists at TUM have discovered a new class of designed macrocyclic peptides that are highly potent inhibitors of amyloid formation, which could be an alternative to current antibody-based approaches. The researchers are now planning further investigations to verify their effectiveness in in vivo models.
BACE inhibitors may fail Alzheimer's trials due to impaired differentiation of newborn cells, according to a study published in eNeuro. The research suggests that partial BACE inhibition could represent an alternative strategy for reducing AD pathology while maintaining adult neurogenesis.
Meytal Landau is honored for her creative and committed work on amyloid-like fibers and alpha-helical structures. The Biophysical Society recognizes her contributions to advancing scientific knowledge and promoting diversity in researchers.
Researchers used proteomics to study the basic biology of Alzheimer's disease, cancer, and listeriosis. They found that BACE1 inhibition increases amyloid precursor protein and other substrates in Alzheimer's, while butyrate activates mitochondrial oxidation and suppresses tumor growth in colorectal cancer cells.
Researchers propose native state is a 'fortunate trap' that prevents spontaneous folding into fibril state, associated with Alzheimer's and Parkinson's diseases. The amyloid state is more stable thermodynamically, but kinetic barriers prevent its formation.
A study published in The Journal of Neuroscience found that low-dose aspirin may reduce plaques in the brain by stimulating lysosomes and increasing the activity of TFEB, a protein responsible for waste removal. This could lead to improved treatment options for Alzheimer's disease.
Researchers found that green tea and red wine compounds can prevent the accumulation of toxic metabolites, which cause severe developmental disorders. This discovery could pave the way for new therapies to treat inborn congenital metabolic diseases.
Researchers found that resveratrol inhibits mutant p53 protein aggregation, preventing breast cancer cell migration and proliferation. This breakthrough could lead to a treatment for over half of malignant tumors, targeting novel strategic targets in cancer research.
Researchers found that extra copies of genes on chromosome 21 increase Alzheimer's-like brain pathology in a mouse model of Down syndrome. The study could lead to future medicines to prevent early onset Alzheimer's disease in people with Down syndrome.
A Penn study found that protein fragments in semen enhance Ebola virus transmission and protect the virus from environmental stress. Researchers suggest targeting amyloids could prevent sexual transmission of the Ebola virus.
A new study reveals that N-acetylaspartate (NAA) molecules can inhibit the clumping of amyloid-beta proteins, which are associated with cognitive decline and neurological problems. By restoring NAA levels after head trauma or in neurological diseases, it may be possible to block the progression of amyloid pathologies.
Researchers identify chemically reduced iron species in brains affected by Alzheimer's, including a magnetic iron oxide called magnetite, which may contribute to disease toxicity. The study suggests that understanding these metals could lead to more effective therapies for Alzheimer's disease.
The new molecules are formed by a chain of 7 amino acids, each composed of only two different amino acids. These peptides have numerous applications, including generating electrical nanoconductors and fibrillar mini enzymes capable of acting as catalysts in the formation of organic nanomaterials.
Exosomes in brains affected by Alzheimer's disease contain toxic aggregates of amyloid beta and tau proteins, spreading the disease to new neurons. The study opens up the possibility of diagnosing Alzheimer's disease and developing drugs that could prevent the spreading.
Amyloid peptides prevent CamKII from participating in synaptic plasticity, leading to synapse loss and cognitive deficiencies. Researchers aim to understand the molecular mechanism behind amyloid aggregate interactions with CamKII to develop potential treatments for early Alzheimer's disease.
Research reveals that alcohol impairs microglial cells' ability to clear amyloid beta, contributing to Alzheimer's disease development. The study found altered gene expression for 312 genes under alcohol exposure.
A research group has developed a new technique to study the behavior of p53 conformers, which are prone to forming amyloid aggregates that contribute to cancer development. The approach allows researchers to observe these conformers before they aggregate, providing potential tools for understanding and blocking their formation.
Researchers found that APOE4 promotes beta amyloid protein accumulation, leading to Alzheimer's pathology. They also discovered that editing the gene can eliminate signs of Alzheimer's in brain cells.
Researchers have discovered that a compound found in green tea can break up potentially dangerous protein plaques in the blood vessels, which can reduce the flow of blood to the heart and brain. This discovery could lead to new medicines to treat heart attack and stroke.
Researchers found that combined vascular risk factors and high brain amyloid levels predict faster cognitive decline in clinically normal older individuals. Vascular risk remained a strong predictor of cognitive decline even when controlling for other biomarkers.
Researchers have identified a mutation that can reduce amyloid-beta plaque accumulation in mice, a hallmark of Alzheimer's disease. The study found that mice with the mutated APP gene had less amyloid-beta build-up, suggesting a potential therapeutic target.
Researchers used a powerful X-ray laser to analyze amyloid proteins, which are linked to neurodegenerative diseases like Alzheimer's. The new method allows for detailed structural analysis of individual amyloid fibrils, enabling scientists to better understand their role in disease development.
Researchers found that brain cholesterol triggers amyloid-beta protein clusters, a key player in Alzheimer's disease. The study suggests targeting cholesterol regulation as a potential treatment approach.
Researchers have created a rat model that can be used to study the buildup of amyloid plaques and vascular abnormalities in the brain, two key traits of Alzheimer's disease. The model, which uses human APP and PS1 proteins, has shown poor memory and learning in rats, similar to those observed in humans suffering from Alzheimer's.
Researchers from Chalmers University of Technology have discovered that a protein called parvalbumin, found in many fish species, can form amyloid structures that bind to and neutralize the 'Parkinson's protein' alpha-synuclein. This could potentially help prevent the formation of harmful amyloids associated with Parkinson's disease, a...
Researchers found that combining two approaches to reduce amyloid-beta improved spatial navigation and memory in a mouse model of Alzheimer's disease. The study suggests similar combination treatments may help patients with Alzheimer's disease in the future.
A study led by researchers at Linköping University found that amyloid beta, a protein linked to Alzheimer's disease, has different properties in different cell types. Glial cells can produce mature, less harmful forms of the protein, while neurons are more susceptible to damage.
Researchers discovered that the apoE4 gene causes damage in human brain cells by altering its main structure and function. They found that adding a small molecule structure corrector eliminates signs of Alzheimer's disease, restores normal cell function, and improves survival in human apoE4 neurons.
Researchers at McGovern Medical School are studying how protein deposits in the brain can trigger dementia and stroke. Akihiko Urayama's team is examining the brain's clearance system, while Louise McCullough's team is investigating the gut-brain connection.
A new blood test has been developed to detect early indicators of Alzheimer's disease, measuring the relative amounts of pathological and healthy amyloid-beta forms in the blood. The test was found to reliably detect signs of the disease on average eight years before diagnosis, with an overall diagnostic accuracy of 86%.
Researchers at WashU Medicine have developed an antibody that targets APOE protein, leading to the removal of amyloid plaques from mouse brains. This breakthrough could potentially halt brain damage triggered by plaques in early stages of Alzheimer's disease.
Researchers at WashU Medicine found a direct correlation between amyloid plaques and tau protein production in the brain. Targeting tau production may lead to new treatments for Alzheimer's disease.
A new biocompatible catalyst selectively oxygenates and degrades amyloid-β peptide under near-infrared light irradiation, reducing its pathogenic properties. The catalyst is applicable for treating peripheral amyloid diseases and Alzheimer's disease.
Researchers discover TREM2 receptor mediates anti-amyloid toxicity, potentially preventing or reducing neurodegenerative disorders like Alzheimer's. Boosting TREM2 levels in the brain may prevent disease progression and restore cognitive function.
Four neuroscientists, including Christian Haass, receive the Brain Prize for their work on the genetic and molecular bases of Alzheimer's disease. Their research has revolutionised understanding of the changes in the brain that lead to Alzheimer's, with potential implications for diagnosis, treatment, and prevention.
Researchers found that a compound enhanced protein trafficking reduced amyloid beta and Tau protein production in brain cells. The study suggests targeting endosomal network defects as a promising strategy against Alzheimer's disease.
Researchers at ETH Zurich have made a groundbreaking discovery that protein amyloids can self-replicate, challenging the long-held RNA hypothesis as the origin of life. The findings suggest that early life forms may have used amyloids as information carriers and catalytic units.
A Canadian study found that individuals close to their parent's onset age of Alzheimer's are more likely to have amyloid plaques in their brain. The research also suggests a stronger link between parental age, ApoE4 gene carriers, and increased disease risk.
A new data analysis of 51 existing studies in mice reveals that phosphorylated tau (p-tau) is a more likely culprit in Alzheimer's disease than previously thought. The study also found that multiple biochemical actors work together to tear down neurons, and that soluble amyloid-beta has a strong correlation with cognitive decline.
A new study challenges the long-held assumption that amyloid beta buildup in brain cells is the origin of Alzheimer's disease. Researchers found that standard diagnostic tools fail to detect future AD in many patients under age 70, and that a decline in cerebrospinal fluid clearance may be the early feature of AD.
A new study reveals that people with preclinical Alzheimer's disease experience significant disruptions in their internal body clocks, even after controlling for other factors. These circadian rhythm disruptions are linked to increased risk of developing the disorder and may serve as a biomarker for early detection.
A large clinical trial found that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease, did not significantly slow cognitive decline. Researchers propose alternative strategies and ongoing studies may lead to effective treatments.
Researchers find that beta amyloid protein disrupts mitochondria function, leading to early disease symptoms. Human cells can be protected from damage with a custom-designed compound, offering an exciting avenue for future drug development.
Researchers analyze brain slices from patients with Alzheimer's and cerebral amyloid angiopathy, finding distinct amyloid-beta prion strains associated with different disease types. Mutant amyloid-beta adopts self-propagating prion structure, imparting pathological conformation to normal amyloid-beta.
Researchers at Hong Kong Baptist University have invented multifunctional cyanine compounds that can be used for detection, imaging and treatment of Alzheimer's disease. The discovery has been granted US patents and a Chinese patent.
Researchers have developed small shining molecules that can recognize specific proteins in the brain, such as amyloid beta and tau. These molecules emit light at different wavelengths when bound to their target protein, enabling potential diagnostic tools for neurodegenerative diseases.
Researchers propose a new term, mapranosis, to describe the interaction between gut microbiota and brain proteins that contributes to neurodegenerative diseases. The process involves amyloid protein misfolding and inflammation in the nervous system.
A study by Temple University researchers found that mice fed canola oil daily suffered impaired working memory and increased amyloid plaques, indicative of neuronal damage. The findings suggest that long-term consumption of canola oil may be detrimental to brain health.
Researchers identified a compound targeting APOE protein in mouse brains, reducing amyloid beta plaques and neurological damage. The findings suggest APOE could be a potential target for treatment or prevention of Alzheimer's disease.
Researchers discovered that enhancing mitochondrial defenses can reduce amyloid plaque formation and improve cognitive function in Alzheimer's disease. The approach targets the mitochondrial unfolded protein response and mitophagy mechanisms to restore cellular energy production and protect against neurodegeneration.
A new PET tracer has been developed to effectively gauge the effectiveness of promising Alzheimer's treatments in mouse models. The tracer binds to BACE1, a key enzyme involved in amyloid-β development, and accurately measures its effects on brain metabolism, neuroinflammation, and amyloid-β pathology.
Researchers have discovered a small-molecule drug that can restore brain function and memory in mice with Alzheimer's-like symptoms by blocking toxic ion flow. The drug, anle138b, attaches to amyloid-beta protein clusters and deactivates pores, reducing neuronal dysfunction and cell death.
A new algorithm can speed up protein-folding simulations, allowing researchers to model phenomena that were previously out of reach. This technique can help scientists better understand and treat diseases like Alzheimer's, which is associated with amyloid-beta protein fragments forming hard plaques that disrupt neurons.